Case 01
GALILEO
Autonomous therapeutic discovery by an embodied AI scientist
Generalizable Agentic Laboratory Intelligence for Learning, Experimentation, and Optimization
GALILEO is the DFM idea made concrete in the life sciences: AI is no longer a tool that completes a single task but enters a real research environment, starts from a real question, keeps learning from experimental feedback and takes part in the whole process of discovery. The work is available as a bioRxiv preprint (June 2026).
- Research question
Most AI systems in biomedicine stop at prediction: predicting targets, predicting molecular properties, without reaching real experimental intervention. GALILEO asks whether AI can move past prediction and close the loop autonomously in a dynamic membrane system, from candidate peptide discovery to wet-lab validation, and find therapeutic targets and molecules that intervene in tumour immunity.
- What was already in place
- A clinically informed peptide prior library (CPP) giving candidates a traceable starting point
- A robotic solid-phase peptide synthesis platform that synthesises AI-designed molecules automatically
- Multimodal phenotyping across membrane current, metabolic flux and T-cell function
- Public omics data from TCGA, CPTAC, GEO and GTEx, plus a wet-lab validation team
- How AI takes part
GALILEO runs on an OTAS reasoning loop (Observation, Thought, Action, Summary) and executes autonomously:
- Retrieving candidates from the peptide prior library and editing sequences through auditable local operations
- Ranking target branches on its own, prioritising the LRRC8C and SLC25A1 pathways
- Updating target beliefs, sequence strategy, assay design and mechanistic hypotheses from wet-lab feedback
- Keeping the whole process traceable and auditable, so scientists can inspect and intervene at any point
- Stage of progress
- The loop from prediction to intervention has been validated and released as a bioRxiv preprint
- Generated peptides blocked LRRC8C current, perturbed osmotic and redox homeostasis and promoted tumour-dependent T-cell activation
- Peptides on the SLC25A1 branch disrupted citrate export metabolism, reduced extracellular acidosis and strengthened CD8+ T-cell function
- Publication and translation are under way; case details will be disclosed progressively once researchers authorise it
The DFM viewGALILEO shows what DFM argues for: moving from completing research tasks to taking part in discovery. AI enters a real research environment, meets the questions scientists actually care about, works with incomplete data and real constraints, and keeps learning from experiments and reality, so each exploration becomes the starting point of the next discovery.
bioRxiv preprint ↗